Projected Price to Earnings: Instil Bio Inc (TIL)

Graphic logo of Instil Bio Inc (TIL)

The quotes provided below on GURU.Markets show a Forward P/E of 0.00. Currently, Instil Bio, Inc. (TIL) is struggling with a liquidity shortage, depleting its reserves to shift its strategic direction. However, the implementation of an exclusive treatment method makes the firm the sole player in its niche, guaranteeing a steady cash flow from the delivery of high-tech medical services for the destruction of resistant neoplasms.

TIL - instilbio.com Projected Price to Earnings over the range 07/04/2022 - 11/11/2026

Analytical breakdowns for Instil Bio Inc (TIL)

- current price and projected stock value:
Stock Quotes Instil Bio|TIL - Average Forecast Price
- company stock exchange capitalization indicators:
Market Valuation Instil Bio Inc.|TIL - Value Adjusted for Debt and Cash
- issuer book value statistics:
Book Value per Share Instil Bio|TIL - Company Net Assets|Market Capitalization to Book Value Ratio instilbio.com|TIL - Company Assets
- debt burden and liquidity indicators:
Debt to Equity Instil Bio, Inc.|TIL - Long-Term Debt to Equity|Short-Term Debt to Equity Instil Bio, Inc.|TIL - Company Debts|Debt to Book Value Instil Bio Inc.|TIL - Company Long-Term Loans and Borrowings|Company Short-Term Debts Instil Bio|Quick Ratio instilbio.com
- earnings and market ratios statistics:
TIL - Company Net Income|Expected Profit Instil Bio, Inc.|TIL - Price to Earnings Multiple|Forward P/E Multiple Instil Bio, Inc|TIL - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio Instil Bio Inc.|TIL - Income before deduction of interest, taxes and amortization|Net earnings per share for the last 12 months Instil Bio|TIL - Earnings per share for the last four quarters|Quarterly EPS earnings growth instilbio.com|TIL - Earnings per share increase in current year|Earnings growth forecast for next year Instil Bio, Inc.
General company analysis:Instil Bio TIL
Signature product of Instil Bio, Inc.

Instil Bio, Inc. (TIL) operates in the non-cyclical cell therapy sector, where business value is driven by clinical trial success rather than macroeconomics. Under these conditions, the forward P/E ratio compares market capitalization with the expected net income for the following year. This multiple measures the premium investors are willing to pay for future cash flows. A decrease in this ratio reduces the risk of overpaying for the asset. By analyzing the changes in the company's forward price-to-earnings multiple, one can assess the current fairness of its market valuation.

Direct competitors

Projected Price to Earnings LEGN (Legend Biotech Corporation)|SANA - Projected Price to Earnings Ratio|Autolus Pharma - Projected Price to Earnings|Future Price to Earnings Multiple ALLO|Cartesian Therapeutics - Forward P/E Multiple|Cellectis S.A. (CLLS) - Projected Price to Earnings|CRBU: Forward P/E Multiple|Projected Price to Earnings Ratio Genenta Science (GNTA)|Future Price to Earnings Century Tx|Future Price to Earnings JSPR|Future Price to Earnings Senti Biosciences, Inc. (SNTI)|Future Price to Earnings ADAP (adaptimmune.com)|CERo Therapeutics Holdings - Projected Price to Earnings|Future Price to Earnings Multiple TCRT|Achilles Tx - Forward P/E Multiple|Forward Price to Earnings Multiple CARGO Therapeutics, Inc (CRGX)|PSTX: Forward P/E Multiple|Projected Price to Earnings Ratio 2seventybio.com (TSVT)|Future Price to Earnings Gracell Biotechnologies Inc.